Biopharmaceuticals developer Imugene recently reported a decrease in its loss after tax to $1.91 million from a loss of $2.30 million a year earlier.

Imugene specialises in the development and commercialisation of animal health biopharmaceuticals, such as vaccines and productivity enhancers for pigs and poultry.